Andrew Brodbelt1, David Greenberg2, Tim Winters3, Matt Williams4, Sally Vernon5, V Peter Collins6. 1. The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool L9 7LJ, UK. Electronic address: abrodbelt@doctors.org.uk. 2. National Cancer Registration Service, Public Health England, Unit C, Magog Court, Hinton Way, Cambridge CB22 3AD, UK. Electronic address: David.greenberg@nhs.net. 3. Knowledge and Intelligence (East), Public Health England, IPH, University Forvie Site, Robinson Way, Cambridge CB2 0SR, UK. Electronic address: Tim.winters@nhs.net. 4. Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Rd, London W6 8RF, UK. Electronic address: Matthew.williams2@imperial.nhs.uk. 5. National Cancer Registration Service, Public Health England, Unit C, Magog Court, Hinton Way, Cambridge CB22 3AD, UK. Electronic address: Sally.vernon@ecric.nhs.uk. 6. Department of Pathology, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK. Electronic address: Vpc20@cam.ac.uk.
Abstract
AIMS: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumour in adults, with a poor prognosis. Changing treatment paradigms suggest improved outcome, but whole nation data for England is scarce. The aim of this report is to examine the incidence of patients with glioblastoma in England, and to assess the influence of gender, age, geographical region and treatment on outcome. METHODS: A search strategy encompassing all patients coded with GBM and treated from January 2007 to December 2011 was obtained from data linkage between the National Cancer Registration Service and Hospital Episode Statistics for England. RESULTS: There were 10,743 patients coded with GBM in this 5-year period (6451 male, 4292 female), giving an overall national age standardised incidence of 4.64/100,000/year. Incidence increases with age. Median survival overall was 6.1 months. One, 2 and 5-year survivals, were 28.4%, 11.5% and 3.4% respectively. Age stratified median survivals decreased significantly (p<0.0001) with increasing age from 16.2 months for the 20-44 year age group, to 7.9 months for the 45-69 years, and 3.2 months for 70+years. In the maximal treatment subgroup, patients aged up to 69 years had a median survival of 14.9 months. Patients over 60 years were less likely to receive maximal combination treatment but median survival was better with maximal treatment at all ages. CONCLUSIONS: The overall outcome for patients with GBM remains poor. However, aggressive treatment at every age group is associated with extended survival similar to that described in clinical trials.
AIMS: Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumour in adults, with a poor prognosis. Changing treatment paradigms suggest improved outcome, but whole nation data for England is scarce. The aim of this report is to examine the incidence of patients with glioblastoma in England, and to assess the influence of gender, age, geographical region and treatment on outcome. METHODS: A search strategy encompassing all patients coded with GBM and treated from January 2007 to December 2011 was obtained from data linkage between the National Cancer Registration Service and Hospital Episode Statistics for England. RESULTS: There were 10,743 patients coded with GBM in this 5-year period (6451 male, 4292 female), giving an overall national age standardised incidence of 4.64/100,000/year. Incidence increases with age. Median survival overall was 6.1 months. One, 2 and 5-year survivals, were 28.4%, 11.5% and 3.4% respectively. Age stratified median survivals decreased significantly (p<0.0001) with increasing age from 16.2 months for the 20-44 year age group, to 7.9 months for the 45-69 years, and 3.2 months for 70+years. In the maximal treatment subgroup, patients aged up to 69 years had a median survival of 14.9 months. Patients over 60 years were less likely to receive maximal combination treatment but median survival was better with maximal treatment at all ages. CONCLUSIONS: The overall outcome for patients with GBM remains poor. However, aggressive treatment at every age group is associated with extended survival similar to that described in clinical trials.
Authors: Nicholas F Brown; Matthew Williams; Hendrik-Tobias Arkenau; Ronald A Fleming; Jerry Tolson; Li Yan; Jianping Zhang; Rajendra Singh; Kurt R Auger; Laurie Lenox; David Cox; Yvonne Lewis; Christophe Plisson; Graham Searle; Azeem Saleem; Sarah Blagden; Paul Mulholland Journal: Neuro Oncol Date: 2018-11-12 Impact factor: 12.300
Authors: Daniel I Hoffman; Kalil G Abdullah; Makayla McCoskey; Zev A Binder; Donald M O'Rourke; Arati S Desai; MacLean P Nasrallah; Ashkan Bigdeli; Jennifer J D Morrissette; Steven Brem; Stephen J Bagley Journal: J Neurooncol Date: 2019-09-21 Impact factor: 4.130
Authors: Michael G Brandel; Robert C Rennert; Christian Lopez Ramos; David R Santiago-Dieppa; Jeffrey A Steinberg; Reith R Sarkar; Arvin R Wali; J Scott Pannell; James D Murphy; Alexander A Khalessi Journal: J Neurooncol Date: 2018-04-24 Impact factor: 4.130
Authors: Daniel M Fountain; Andrew Bryant; Damiano Giuseppe Barone; Mueez Waqar; Michael G Hart; Helen Bulbeck; Ashleigh Kernohan; Colin Watts; Michael D Jenkinson Journal: Cochrane Database Syst Rev Date: 2021-01-04